Articles Mentioning Pharmaceuticals Stocks

Results 1 - 10 of 955 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals

Investing | January 27, 2015

Bristol-Myers Squibb Co.'s Fourth Quarter Earnings Warn of a Tough Year Ahead

Bristol-Myers Squibb Co. reported its fourth quarter earnings Tuesday morning. Here's what investors need to know.

Investing | January 27, 2015

Pfizer, Inc. Should Forget AstraZeneca and Buy This Company Instead

3 Motley Fool contributors offer up suggestions on what they believe Pfizer should acquire.

Investing | January 24, 2015

This Stock Could Become the Next Johnson & Johnson

Our Motley Fool contributors think that these three companies could one day be as revered as J&J.

Investing | January 20, 2015

Can AbbVie Inc. Overcome Humira’s Looming Patent Expiration?

AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?

Investing | January 15, 2015

AbbVie Inc.'s Insights at the JP Morgan Healthcare Conference

AbbVie highlighted its hepatitis C and oncology growth opportunities at the annual JP Morgan Healthcare Conference.

Investing | January 12, 2015

Why Shares of Foundation Medicine, Inc. Skyrocketed Today

Shares of cancer diagnostic maker Foundation Medicine more than doubled Monday morning. Here's why.

Investing | January 11, 2015

5 Predictions for Biotechnology Stocks in 2015

Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.

Investing | January 11, 2015

3 Ways Gilead Sciences, Inc. Could Still Be in Big Trouble

There are few stocks as exciting as Gilead Sciences. But, that doesn't mean there aren't headwinds which could send its shares significantly lower. Here are three such headwinds that Wall Street may be overlooking.

Investing | January 09, 2015

Is Gilead Sciences Inc. Now a Takeover Target?

Gilead Sciences looks cheap based on its present valuation metrics and growth prospects going forward. Will a growth-starved big pharma decide to pursue a merger with this high flying biotech in 2015?

Investing | January 08, 2015

Is AbbVie Inc. Ripe for a Buyout?

After failing to complete a buyout of Irish biopharma Shire, AbbVie was reported to be a potential takeover target. Is this top drugmaker an attractive acquisition target for growth-starved big pharma in 2015?

Results 1 - 10 of 955 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals